Linezolid was tested against 70 strains of Helicobacter pylori by the agar dilution method. The MIC range and MICs at which 50 and 90% of strains were inhibited were 8 to 64, 16, and 32 microgram/ml, respectively. With minimum and maximum fractional inhibitory concentration summation values of 0.31 and 2.50, respectively, the combination of linezolid with amoxicillin, clarithromycin, or metronidazole showed either partial synergy or indifference for the majority of strains.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89996 | PMC |
| http://dx.doi.org/10.1128/AAC.44.7.1977-1979.2000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
resistance in Hainan Province, China: investigating phenotypes and genotypes through whole-genome sequencing.
Front Cell Infect Microbiol
January 2025
Department of Gastroenterology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
is increasingly resistant to antibiotics, significantly lowering eradication rates and posing a major public health challenge. This study investigated the distribution of antibiotic-resistant phenotypes and genotypes of in Hainan Province. It determined the minimum inhibitory concentrations (MICs) of six antibiotics using the E-test method and detected resistance genes via Sanger sequencing.
View Article and Find Full Text PDFAsia-Pacific Survey on the Management of Helicobacter pylori Infection.
J Gastroenterol Hepatol
December 2024
Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
Background And Aim: Gastric cancer (GC)-related incidence and mortality rates remain high owing to Helicobacter pylori infection in Asia, and the importance of primary and secondary prevention of GC has been well recognized. We aimed to investigate the extent of overall agreement among clinicians in the Asia-Pacific region regarding the management of H. pylori infection.
View Article and Find Full Text PDFDurlobactam in combination with β-lactams to combat .
Antimicrob Agents Chemother
December 2024
Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA.
() presents significant clinical challenges. This study evaluated the synergistic effects of a β-lactam and β-lactamase inhibitor combination against and explored the underlying mechanisms. Synergy was assessed through MIC tests and time-kill studies, and binding affinities of nine β-lactams and BLIs to eight target receptors (L,D-transpeptidases [LDT] 1-5, D,D-carboxypeptidase, penicillin-binding protein [PBP] B, and PBP-lipo) were assessed using mass spectrometry and kinetic studies.
View Article and Find Full Text PDFGlobal prevalence of Helicobacter pylori antibiotic resistance among children in the world health organization regions between 2000 and 2023: a systematic review and meta-analysis.
BMC Med
December 2024
Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Background: Helicobacter pylori infection causes gastritis, peptic ulcers, and gastric cancer. The infection is typically acquired in childhood and persists throughout life. The major impediment to successful therapy is antibiotic resistance.
View Article and Find Full Text PDFAnalysis of antibiotic susceptibility and genomic characteristics of Helicobacter pylori by whole-genome resequencing in Northern China.
Braz J Microbiol
December 2024
National Center for Clinical Laboratories, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology, Beijing, P.R. China.
Introduction: Helicobacter pylori (H. pylori) is a major human pathogen whose increased antibiotic resistance poses a serious threat to human health.
Aim: The aim of this study is to further explore the association between H.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!